/
LIXT
$8.04+$0.85 (+11.82%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$125.0M
17M shares
52-week range
$0.68 – $8.25
97% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
16.44%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-23.26
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $40.7K | $820.9K | $1.2M | $1.7M | $1.3M | $898.1K | $726.2K | $254.9K |
| Operating income | −$2.1M | −$2.5M | −$3.3M | −$6.7M | −$6.3M | −$5.1M | −$3.6M | −$5.1M |
| EBITDA | $4.9K | −$2.4M | $0 | −$6.7M | −$6.3M | −$5.1M | −$3.6M | −$6.0M |
| Net income | −$2.1M | −$2.4M | −$3.3M | −$6.7M | −$6.3M | −$5.1M | −$3.6M | −$6.0M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -2.18 | -2.20 | -2.89 | -5.00 | -4.00 | -2.66 | -1.59 | -1.26 |
Annual figures · source: Financial Modeling Prep
Peer comparison
Lixte Biotechnology Holdings, Inc. Common Stock
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.
www.lixte.com- Employees
- 3
- IPO / List date
- Sep 5, 2007
- HQ
- BOCA RATON, FL
Held by traders on TradeandTell
No one on the platform currently holds LIXT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 93,000 | $285.5K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-06-05 | 1-for-10reverse |
| 2020-11-20 | 1-for-6reverse |
Recent trades on TradeandTell
No one on the platform has traded LIXT yet.
